Search

Your search keyword '"Rasche, Leo"' showing total 670 results

Search Constraints

Start Over You searched for: Author "Rasche, Leo" Remove constraint Author: "Rasche, Leo"
670 results on '"Rasche, Leo"'

Search Results

1. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

4. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

7. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

8. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?

10. Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma

11. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

12. Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1

16. Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy

17. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

18. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

19. Tumour Escape from CAR-T Cells

27. Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies

28. Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

31. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

33. Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.

36. Lymphocyte and neutrophil count combined with intestinal bacteria abundance predict the severity of COVID-19

37. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia

39. Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment—67 Patients Multicenter Analysis.

40. Venetoclax salvage therapy in relapsed/refractory multiple myeloma

41. Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma

42. OA-23 Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis

43. MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

44. P-417 SKY92 gene expression profiling and cytogenetics according to R2-ISS for multiple myeloma risk classification

45. POSTER: MM-191 Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1

46. OA-24 Sequential and persistent loss of BCMA and GPRC5D after bispecific antibodies in multiple myeloma revealed by whole genome sequencing

47. P-489 Prolonged cytopenia after CAR T-cell therapy in multiple myeloma: results from a prospective comprehensive biomarker study

48. P-480 Outcome of pneumocystis jirovecii pneumonia in patients with multiple myeloma

49. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma

Catalog

Books, media, physical & digital resources